The First Affiliated Hospital of Army Military Medical University
Welcome,         Profile    Billing    Logout  
 6 Trials 
12 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chen, Lei
LUCENT-1, NCT03518086 / 2017-003229-14: An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

Checkmark Full data from P3 LUCENT 1 trial for severe ulcerative colitis
Oct 2022 - Oct 2022: Full data from P3 LUCENT 1 trial for severe ulcerative colitis
Checkmark Efficacy and safety data from LUCENT-1 trial for moderately-to-severely active ulcerative colitis
Feb 2022 - Feb 2022: Efficacy and safety data from LUCENT-1 trial for moderately-to-severely active ulcerative colitis
Checkmark From LUCENT 1 trial for ulcerative colitis
More
Completed
3
1281
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828, Placebo
Eli Lilly and Company
Ulcerative Colitis
01/21
05/24
LUCENT-2, NCT03524092 / 2017-003238-96: A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Checkmark Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
May 2022 - May 2022: Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
Checkmark Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Dec 2021 - Dec 2021: Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Active, not recruiting
3
1177
Europe, Canada, Japan, US, RoW
Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC
Eli Lilly and Company
Ulcerative Colitis
11/21
12/24
TQB2450-III-08, NCT04809142: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer

Recruiting
3
392
RoW
TQB2450 Injection, Anlotinib hydrochloride, Oxaliplatin injection, Capecitabine tablets, Gemcitabine hydrochloride injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Biliary Cancer
03/22
02/23
NCT05862337: Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

Recruiting
3
480
RoW
Anlotinib hydrochloride capsules, Penpulimab injection, Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hepatocellular Carcinoma
08/24
12/26
NCT06492460: 2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma

Recruiting
3
422
RoW
Drug:Cisplatin, CDDP Drug
Sun Yat-sen University, Hunan Cancer Hospital, Guilin Medical University, China, Jiangsu Cancer Institute & Hospital, Xiangya Hospital of Central South University
Squamous Cell Carcinoma of Head and Neck
09/29
07/33
NCT06738979: A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects

Not yet recruiting
3
408
RoW
TQF3510 (Semaglutide Injection), Wegovy®
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Obesity
07/26
08/26
TSL-CM-JSSPMFSL-Ⅲ, NCT06068465: A Study of the Safety and Efficacy of Pimavanserin in Patients with Parkinson's Disease Psychosis

Recruiting
3
248
RoW
pimavanserin tartrate, placebo
Tasly Pharmaceutical Group Co., Ltd
Parkinson's Disease Psychosis
06/25
01/26
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
NCT03977480: Phase II Study of Hemay007 in Patients With Active Ulcerative Colitis

Terminated
2
70
RoW
Hemay007, Placebo
Tianjin Hemay Pharmaceutical Co., Ltd
Ulcerative Colitis
08/22
08/22
NCT06481085: To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus

Not yet recruiting
2
318
RoW
HDM1002 50 mg, HDM1002, HDM1002 100 mg, HDM1002 200 mg, HDM1002 400 mg, HDM1002 200 mg BID, Placebo, Matching placebo for group A to group E
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Type 2 Diabetes
04/25
04/25
NCT06493747: Acupuncture + Neuromodulation for Post-Stroke Aphasia

Recruiting
N/A
82
RoW
Combined Low- and High-Frequency rTMS Intervention, Combined High- and Low-Frequency rTMS Intervention, rTMS, rTMS + Acupuncture, Control Group, Acupuncture
Shanghai Yueyang Integrated Medicine Hospital
Aphasia, Rehabilitation
10/24
01/25
NCT06762613: AI Guided System for Lung Puncture Procedure.

Not yet recruiting
N/A
220
RoW
Generative AI Based Puncture Surgery Navigation System, Cone beam CT
Wuhan Union Hospital, China
Lung Nodules
05/25
05/25

Download Options